Timuçin Çil

机构：Sağlık Bilimleri Üniversitesi, University of Health Sciences, University of Health Sciences Antigua · ORCID：0000-0002-5033-1479

发表论文 156 篇 · 总被引 2009 次 · h-index 19

代表论文

• Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer (2025 · New England Journal of Medicine · 被引 128)
• Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. (2025 · Journal of Clinical Oncology · 被引 14)
• PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (2025 · Journal of Hematology & Oncology · 被引 10)
• Systemic Immune-Inflammation Index as a Prognostic Marker in Gastric and Gastroesophageal Junction Cancers Receiving Perioperative FLOT Therapy (2025 · Medicina · 被引 10)
• PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer (2026 · New England Journal of Medicine · 被引 6)
• Prognostic value of inflammatory-nutritional indexes and HALP score in advanced stage NSCLC treated with first-line TKI (2025 · Biomarkers in Medicine · 被引 5)